Hoffman-Rattet v. Ortho Pharmaceutical Corp.

135 Misc. 2d 750, 516 N.Y.S.2d 856, 1987 N.Y. Misc. LEXIS 2299
CourtNew York Supreme Court
DecidedMay 20, 1987
StatusPublished
Cited by9 cases

This text of 135 Misc. 2d 750 (Hoffman-Rattet v. Ortho Pharmaceutical Corp.) is published on Counsel Stack Legal Research, covering New York Supreme Court primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Hoffman-Rattet v. Ortho Pharmaceutical Corp., 135 Misc. 2d 750, 516 N.Y.S.2d 856, 1987 N.Y. Misc. LEXIS 2299 (N.Y. Super. Ct. 1987).

Opinion

OPINION OF THE COURT

Stanley L. Sklar, J.

This application for renewal/reargument of defendant Or-tho Pharmaceutical Corporation’s summary judgment motion raises issues previously unresolved in New York concerning the availability of summary judgment to a pharmaceutical manufacturer based upon an affidavit from an "informed intermediary”, namely, the physician who prescribed the manufacturer’s product.

First, this court holds that the drug manufacturer has the burden of proving, by means of a physician’s affirmative statement, that, even if adequately warned, the treatment provided would have been virtually identical to that actually rendered. Summary judgment is appropriate only when that burden has been met to the level of negating the existence of a genuine factual issue. Second, in attempting to meet that burden, unless the physician’s statement is self-disserving, the issue of the credibility of the physician’s affidavit should ordinarily be left for the trier of the facts and should not be resolved by the court on a motion for summary judgment.

Ortho has failed to provide the necessary evidence to negate the existence of a genuine issue of material fact. In addition, it has failed to establish as a matter of law that it discharged its duty to adequately inform plaintiff’s physician of the newly discovered risks attributed to the intrauterine device.

Accordingly, its application is denied.

ADDITIONAL FACTS

Ortho, in the instant motion, seeks to fill in the gaps in the affidavits appended to its earlier motion.

Specifically, it appends the affidavit of Chris McDowell, an Ortho employee, who states that the "Dear Doctor” letter "was mailed on November 4, 1977 to all obstetricians, gynecologists and family practitioners in the United States”. In addition, Ortho provides the supplemental affidavit of Dr. Storch, in which she claims that "[p]rior to December 1977, I [752]*752received a 'Dear Doctor’ letter and revised package insert for Lippes Loop”. Dr. Storch also states that when she inserted the Lippes Loop into Ms. Hoffman-Rattet, she (Dr. Storch) was aware that "infertility was a possible complication of pelvic infection”. Dr. Storch also reiterates the assertion contained in her original affidavit, namely, that at the time of the insertion she was aware that there was a risk of PID associated with IUDs, including the Lippes Loop. Finally, Dr. Storch claims that she prescribed Lippes Loops after December 1977.

Ortho now argues that this additional data, coupled with that furnished on the original application, establish (1) that the updated material was sent by Ortho to Dr. Storch and that she received it before she saw Ms. Hoffman-Rattet in December 1977, and, therefore, Ortho discharged its duty to adequately warn Dr. Storch; (2) that even if Dr. Storch did not read this new material before seeing Ms. Hoffman-Rattet in December 1977, because Dr. Storch did prescribe the Lippes Loop after December 1977, presumably after she read the update, one can infer that had Dr. Storch read it before seeing Ms. Hoffman-Rattet, any treatment provided would not have varied from that actually rendered; and (3) because Dr. Storch independently knew that some Lippes Loop users suffered from PID and that PID could lead to infertility, her actions constituted an intervening cause of Ms. Hoffman-Rattet’s injuries sufficient to relieve Ortho of all liability as a matter of law.

I shall now address, seriatim, each of these arguments, none of which justifies summary judgment in Ortho’s favor.

UPDATE — CONVEYED/rECEIVED

With respect to whether the new warnings were conveyed, Ortho now provides its employee’s affidavit, confirming that they were sent in November 1977. Aside from the fact that this information could have been provided on the original motion and no excuse has been offered for the failure to do so, because it is an assertion exclusively within the knowledge of the moving party, it is subject to an attack on credibility. (Cohen v St. Regis Paper Co., 64 NY2d 656, 658 [1984].) Although, where an issue of credibility is involved, the granting of summary judgment is generally inappropriate (Frame v Markowitz, 125 AD2d 442 [2d Dept 1986]; Koen v Carl Co., 70 AD2d 695 [3d Dept 1979]), here Dr. Storch also claims to have received the updated warnings. Because it was not necessarily [753]*753in her best interests to so have admitted, the court will assume for purposes of this motion that they were received, i (See, Albouyeh v County of Suffolk, 62 NY2d 681, 683 [1984]; Wolfgruber v Upjohn Co., 72 AD2d 59, 63 [4th Dept 1979], affd 52 NY2d 768.)

Dr. Storch, while admitting that she received the update before seeing the plaintiff in December 1977, never admitted that she (Dr. Storch) read it. If Dr. Storch did not in fact read the new warnings, this may have been due to the inadequacy of the "Dear Doctor” letter.

"An adequate warning is one reasonable under the circumstances. Sterling Drug, Inc. v. Yarrow, 408 F.2d 978, 992, 993 (9th Cir. 1969); Ortho Pharmaceutical Corp. v. Chapman, 388 N.E.2d at 553. A warning may be inadequate in factual content, in expression of the facts, or in the method by which it is conveyed. Ortho Pharmaceutical Corp. v. Chapman, 388 N.E.2d at 552.” (Brochu v Ortho Pharm. Corp., 642 F2d 652, 657 [1st Cir 1981].) The manufacturer must bring home the warnings to the doctor. (Richards v Upjohn Co., 95 NM 675, 625 P2d 1192, 1196 [1980]; Wooderson v Ortho Pharm. Corp., 235 Kan 387, 681 P2d 1038, 1050 [1984], cert denied 469 US 965.) Warnings may be inadequate if they "could have been reasonably found to be lacking in emphasis, timeliness and attention inviting qualities * * * [or where they are] reluctant and lacking in a sense of urgency”. (Sterling Drug v Yarrow, 408 F2d 978, 994 [8th Cir 1969], supra; Ross v Jacobs, 684 P2d 1211, 1214 [Ct App, Okla 1984].)

In the instant case a jury could reasonably find the "Dear Doctor” letter to have been inadequate. As noted above, the letter somewhat reluctantly seemed to indicate that Ortho was only sending it out because the FDA required it of all IUD manufacturers. Thus, a doctor receiving it could believe that the new warning contained generalizations about all IUDs. Dr. Storch, having participated in Lippes Loop studies, may have believed that her specific knowledge about the Lippes Loop superseded any generalized information. Further, the letter made no mention of newly discovered dangers.

Moreover, as also indicated above, the letter suggested that the new FDA regulation dealt with prospective users only in that it stated that "according to the regulation [the Patient Information Booklet] is to be given to all patients who desire a Lippes Loop prior to the insertion”. It also recited that Ortho believed that the doctor would find the booklet and package [754]*754insert useful "when you are considering the Lippes Loop for your patients”.

Accordingly, a jury could find that a physician in Dn Storch’s position might reasonably have believed it unnecessary to read the new materials unless that physician was contemplating prescribing a Lippes Loop for a patient for the first time.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Stephanie Ideus v. Teva Pharmaceuticals USA, Inc.
986 F.3d 1098 (Eighth Circuit, 2021)
Bee v. Novartis Pharmaceuticals Corp.
18 F. Supp. 3d 268 (E.D. New York, 2014)
Anderson v. Hedstrom Corp.
76 F. Supp. 2d 422 (S.D. New York, 1999)
Krasnopolsky v. Warner-Lambert Co.
799 F. Supp. 1342 (E.D. New York, 1992)
Bravman v. Baxter Healthcare Corp.
794 F. Supp. 96 (S.D. New York, 1992)
Palladino v. Gutman
176 A.D.2d 930 (Appellate Division of the Supreme Court of New York, 1991)
Glucksman v. Halsey Drug Co.
160 A.D.2d 305 (Appellate Division of the Supreme Court of New York, 1990)
Ellis v. Allstate Insurance
151 A.D.2d 543 (Appellate Division of the Supreme Court of New York, 1989)

Cite This Page — Counsel Stack

Bluebook (online)
135 Misc. 2d 750, 516 N.Y.S.2d 856, 1987 N.Y. Misc. LEXIS 2299, Counsel Stack Legal Research, https://law.counselstack.com/opinion/hoffman-rattet-v-ortho-pharmaceutical-corp-nysupct-1987.